Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | CD69 | Q07108 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PYGB | P11216 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | OGA | O60502 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12337162 | 1.00 | ALDH1A1 (0.56) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL12295742 | 1.00 | ALDH1A1 (0.56) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL15616403 | 1.00 | ALDH1A1 (0.56) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL13541586 | 1.00 | ALDH1A1 (0.56) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL14823585 | 1.00 | ALDH1A1 (0.56) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL17400176 | 1.00 | ALDH1A1 (0.56) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL14450135 | 1.00 | ALDH1A1 (0.56) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL13773326 | 1.00 | ALDH1A1 (0.56) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL20626631 | 1.00 | ALDH1A1 (0.56) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL12733141 | 1.00 | ALDH1A1 (0.56) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230272385-A1 | siRNAs WITH VINYLPHOSPHONATE AT THE 5' END OF THE ANTISENSE STRAND | SILENCE THERAPEUTICS GMBH (DE) | 2023-08-31 | — | — | US | disclosed |
| EP-4194553-A1 | MODIFIED SIRNA WITH REDUCED OFF-TARGET ACTIVITY | Tuojie Biotech (Shanghai) Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
| WO-2023041079-A9 | LPA INHIBITOR AND USE THEREOF | 上海金中锘美生物医药科技有限公司 | 2023-06-01 | — | — | WO | disclosed |
| WO-2023088427-A1 | SIRNA TARGETING ANGIOTENSINOGEN AND PHARMACEUTICAL USE OF SIRNA | 上海拓界生物医药科技有限公司 | 2023-05-25 | — | — | WO | disclosed |
| US-20220324900-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2022-10-13 | — | — | US | disclosed |
| US-20220195436-A1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF C3 IN A CELL | SILENCE THERAPEUTICS GMBH (DE) | 2022-06-23 | — | — | US | disclosed |
| US-20210395734-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2021-12-23 | — | — | US | disclosed |
| EP-3845547-A1 | GALNAC3 CONJUGATED MODIFIED OLIGONUCLEOTIDE FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2021-07-07 | — | — | EP | disclosed |
| EP-3828275-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2021-06-02 | — | — | EP | disclosed |
| US-20210155926-A1 | siRNAs WITH AT LEAST TWO LIGANDS AT DIFFERENT ENDS | SILENCE THERAPEUTICS GMBH (DE) | 2021-05-27 | — | — | US | disclosed |
| EP-3524680-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2019-08-14 | — | — | EP | disclosed |
| EP-2991661-B1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | IONIS PHARMACEUTICALS INC (US) | 2019-03-13 | — | — | EP | disclosed |
| US-10174069-B2 | Virus detection | ICENI DIAGNOSTICS LIMITED (GB) | 2019-01-08 | — | — | US | disclosed |
| US-9932581-B2 | Compositions and methods for modulating apolipoprotein C-III expression | IONIS PHARMACEUTICALS, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| WO-2018044350-A1 | TARGETING LIGANDS | ARROWHEAD PHARMACEUTICALS, INC (US) | 2018-03-08 | — | — | WO | disclosed |
| US-20170253875-A1 | Targeting Ligands For Therapeutic Compounds | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2017-09-07 | — | — | US | disclosed |
| US-20140274903-A1 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | NOVO NORDISK HEALTHCARE AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20100028939-A1 | Use of Galactose Oxidase for Selective Chemical Conjugation of Protractor Molecules to Proteins of Therapeutic Interest | NOVO NORDISK HEALTHCARE A/G (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230272385-A1 | siRNAs WITH VINYLPHOSPHONATE AT THE 5' END OF THE ANTISENSE STRAND | RNASE1, DCLRE1B, SNRPE | ALDH1A1 3841/4885THRB 3169/4885MAPK1 4136/4885 |
| US-20220324900-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | TEK, PLIN3, FABP3 | ALDH1A1 2808/4885THRB 2520/4885MAPK1 3617/4885 |
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | VIP, PTMS, PDGFA | ALDH1A1 4789/4885THRB 3165/4885MAPK1 2995/4885 |
| US-20170253875-A1 | Targeting Ligands For Therapeutic Compounds | FABP1, SNRPE, HAVCR2 | ALDH1A1 2962/4885THRB 1191/4885MAPK1 4176/4885 |
| US-20210155926-A1 | siRNAs WITH AT LEAST TWO LIGANDS AT DIFFERENT ENDS | NSUN3, SNRPE, RNASE1 | ALDH1A1 2634/4885THRB 722/4885MAPK1 4641/4885 |
| US-20140274903-A1 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | GALE, GALNT2, GALNT1 | ALDH1A1 244/4885THRB 1093/4885MAPK1 3584/4885 |
| US-20210395734-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | APOB, APOL1, LDLR | ALDH1A1 2605/4885THRB 2086/4885MAPK1 4093/4885 |
| US-10174069-B2 | Virus detection | SIGLEC7, SIGLEC9, NEU4 | ALDH1A1 1162/4885THRB 1603/4885MAPK1 2414/4885 |
| US-20100028939-A1 | Use of Galactose Oxidase for Selective Chemical Conjugation of Protractor Molecules to Proteins of Therapeutic Interest | GALE, GALNT2, GALNT1 | ALDH1A1 244/4885THRB 1093/4885MAPK1 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.